CADL
Candel Therapeutics, Inc.5.74
-0.03-0.52%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
315.12MP/E (TTM)
-Basic EPS (TTM)
-0.56Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Candel secures $130M loan facility
Candel Therapeutics secured a $130 million term loan facility from Trinity Capital Inc. on October 14, 2025, drawing $50 million initially to refinance prior debt and fund general operations, with up to $80 million more available via tranches tied to clinical and regulatory milestones. This bolsters the balance sheet alongside $87.2 million in cash as of September 30, 2025, enabling a phase 3 trial of CAN-2409 in NSCLC starting Q2 2026 and prepping for a potential prostate cancer launch. Yet, the company will seek partnerships for CAN-2409 in pancreatic cancer to sharpen focus on high-impact indications. Positive interim data from CAN-3110's phase 1b trial in recurrent glioblastoma showed four of nine patients alive after multiple doses, with mature survival updates due Q4 2026.
8-K
Lease extended three years
Candel Therapeutics extended its lease for 15,197 square feet at 117 Kendrick Street, Needham, Massachusetts, pushing the term to August 31, 2029. Starting September 1, 2026, annual base rent begins at $607,880, rising $15,197 yearly to $638,274 by the final year. This locks in operational continuity. Yet, it commits the biotech to escalating costs amid uncertain funding.
ACTU
Actuate Therapeutics, Inc.
6.96+0.10
ARTL
Artelo Biosciences, Inc.
1.84+0.01
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CLRB
Cellectar Biosciences, Inc.
3.18-0.02
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CUE
Cue Biopharma, Inc.
0.41-0.05
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
VINC
Vincerx Pharma, Inc.
0.01+0.00